Arkolith/Insider Trading/AKBA/Form 4

Grund Nicholas

Chief Commercial OfficerAkebia Therapeutics, Inc. (AKBA) · full profile →Form 4 · filed Feb 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$117K
Net Open-Market Flow
-$117K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2025Sell(S)56K$2.10$117K443K
Jan 31, 2025Grant(A)195K—$0498K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)292K—$0292K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-000914) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML